Status:
COMPLETED
Nexium Dyspepsia/AST
Lead Sponsor:
AstraZeneca
Conditions:
Gastrointestinal Disease
Signs and Symptoms, Digestive
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
The aim is to evaluate if the resolution of upper abdominal symptoms (pain or burning) during an acid suppressive test trial of esomprazole given daily for 7 days predicts symptoms resolution at the e...
Eligibility Criteria
Inclusion
- At least 3 months of symptoms of pain or burning centered in the upper abdomen prior to enrollment.
- Both Helicobacter pylori positive and negative patients eligible (Helicobacter pylori is a bacterial infection of the stomach)
Exclusion
- Presence of clinical significant abnormal findings at the endoscopy (examination of esophagus and stomach) prior to enrollment.
- Patients with symptoms of other gastrointestinal diseases, such as Gastroesophageal Reflux Disease (GERD), Irritable Bowel Syndrome (IBS) or Inflammatory Bowel Disease (IBD).
- Helicobacter pylori eradication treatment during the last 12 months prior to enrollment.
Key Trial Info
Start Date :
December 1 2002
Trial Type :
INTERVENTIONAL
End Date :
January 1 2005
Estimated Enrollment :
1500 Patients enrolled
Trial Details
Trial ID
NCT00251914
Start Date
December 1 2002
End Date
January 1 2005
Last Update
January 24 2011
Active Locations (215)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Buenos Aires, Argentina
2
Research Site
Mendoza, Argentina
3
Research Site
Rosario, Argentina
4
Research Site
San Miguel de Tucumán, Argentina